EFFICIENCY OF SYSTEMIC THERAPY FOR STAGE IV RENAL CELL CARCINOMA IN TERMS OF PROGNOSTIC FACTORS
- Authors: Poluyanchik A.1
-
Affiliations:
- N.N. Aleksandrov Republican Research and Practical Center for Oncology and Medical Radiology
- Issue: Vol 27, No 8 (2016)
- Pages: 46-52
- Section: Articles
- URL: https://journals.eco-vector.com/0236-3054/article/view/116673
- ID: 116673
Cite item
Open Access
Access granted
Abstract
This investigation has evaluated the efficiency of treatment and identified prognostic factors for adjusted survival rates in patients with disseminated kidney cancer treated at the Republican Research and Practical Center for Oncology and Medical Radiology (Minsk) in 1999 to 2011. A prognostic classification has been elaborated for disseminated renal cell carcinoma, in accordance with which patients with less than 2 risk factors are classified into a low-risk group, those with 3-4 and more than 4 risk factors are into medium- and high-risk groups, respectively.
Full Text
About the authors
A. Poluyanchik
N.N. Aleksandrov Republican Research and Practical Center for Oncology and Medical Radiology
Email: poluyanchik@gmail.com
Minsk, Republic of Belarus
References
- Александров Н.Н., Фрадкин С.З. Гипертермия-перекисление в комплексном лечении злокачественных новообразований: Науч. обзор. Под ред. Н.Е. Савченко / М., 1976; 110 с.
- Александров Н.Н., Савченко Н.Е., Фрадкин С.З. Применение гипертермии и гипергликемии при лечении злокачественных опухолей / М.: Медицина, 1980; 256 с.
- Океанов А.Е., Моисеев П.И., Левин Л.Ф. Злокачественные новообразования в Беларуси, 2001-2012. Под ред. О.Г. Суконко / Минск: РНПЦ ОМР, 2013; 373 с.
- Landis S., Murray T., Bolden S. et al. Cancer statistics: 1999 // CA Cancer J. Clin. - 1999; 49: 8-31.
- Pantuck A., Zisman A., Belldegrun A. The changing natural history of renal cell carcinoma // J. Urol. - 2001; 166: 1611-23.
- Motzer R., Mazumdar M., Bacik J. et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma // J. Clin. Oncol. - 1999; 17: 2530-40.
- Heng D. et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study // J. Clin. Oncol. - 2009; 27 (34): 5794-9.
- Isbarn H., Karakiewicz P. Predicting cancer-control outcomes in patients with renal cell carcinoma // Curr. Opin Urol. - 2009; 19: 247-57.
- Cindolo L., de la Taille A., Messina G. et al. A preoperative clinical prognostic model for non-metastatic renal cell carcinoma // BJU Int. - 2003; 92: 901-5.
- Motzer R., Bukowski R., Figlin R. et al. Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma // Cancer. - 2008; 113: 1552-8.
- Motzer R., Bacik J., Murphy B. et al. Interferon-alfa as a comparative treatment for clinical trials of newtherapies against advanced renal cell carcinoma // J. Clin. Oncol. - 2002; 20: 289-96.
- Kim H., Hong M., Kim K. et al. Sunitinib for Asian patients with advanced renal cell carcinoma: a comparable efficacy with different toxicity profiles // Oncology. - 2011; 80: 395-405.
- Coppin C., Porzsolt F., Autenrieth M. et al. Immunotherapy for advanced renal cell cancer // Cochrane Database System. Rev. - 2000; Issue 3: CD001425.
- Hudes G., Carducci M. et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma // N. Engl. J. Med. - 2007; 356 (22): 2271-81.
Supplementary files
